Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study-Reference-Cited by-同舟云学术

Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study

Published:2021-11 Issue:2 Volume:163 Page:392-397
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Wenzel Lari,Huang Helen Q.,Cella David,McKinney Chelsea O.,Zevon Michael A.,LaChance Jason A.,Walker Joan L.,Salani Ritu,Modesitt Susan C.,Morris Robert T.,Bradley William H.,Boente Matthew P.,von Gruenigen Vivian E.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference17 articles.

1. Phase III Trial of Standard-Dose Intravenous Cisplatin Plus Paclitaxel Versus Moderately High-Dose Carboplatin Followed by Intravenous Paclitaxel and Intraperitoneal Cisplatin in Small-Volume Stage III Ovarian Carcinoma: An Intergroup Study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group

2. Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms;Kluetz;Clin. Cancer Res.,2016

3. Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: a prospective analysis;Beesley;Gynecol. Oncol.,2014

4. Symptom burden and outcomes of patients with platinum resistant/refractory recurrent ovarian cancer: a reality check: results of stage 1 of the gynecologic cancer intergroup symptom benefit study;Friedlander;Int. J. Gynecol. Cancer,2014

5. Patient-reported outcome results from the open-label phase iii aurelia trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer;Stockler;J. Clin. Oncol.,2014